INVO Fertility Inc. Common Stock (IVF)

FairStock Score: 24/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look first for a durable business earning consistent profits. INVO Fertility runs fertility clinics and sells the INVOcell device, a niche healthcare service. Revenue has grown: in fiscal 2025 the company reported $6.8 million, up from $6.6 million in fiscal 2024 and $3.0 million in fiscal 2023. But the bottom line tells a harsher story: fiscal 2023 net loss $8.0 million, fiscal 2024 net loss $9.3 million, fiscal 2025 net loss $23.3 million. The latest filed quarter, fiscal Q2 2026 ended 2026-06-30, showed revenue $2.2 million and net income $888,740, a 40.85% margin, but fiscal Q1 2026 was a $5.5 million loss. One profitable quarter does not create a moat. The business is tiny, with a $1.6 million market cap at the 2026-10-13 close of $0.64, and trailing free cash flow was negative $4.8 million, a -299.7% FCF yield on that market cap. The FairStock ratios show P/B 0.09 and a Graham Number of $262.23, implying a 99.76% margin of safety, but I am wary: Altman Z-Score -5.27 signals financial distress, Piotroski is only 4/9, and the company has lost money in each of the last four years. Low price-to-book can be a value trap when assets are uncertain and cash burn is heavy. Growth is real, but until profits and cash flow are consistently positive, this is speculation, not a Graham-style bargain.

In plain English: The company provides fertility treatments and a device used in fertility care. Its annual results have lost money and it burns cash, so the business looks financially weak. At 64 cents a share, the market value is tiny compared with its sales and what its books say it owns, but the cheap-looking price comes with high risk because profits are not steady.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer